• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Roivant Sciences Ltd.

    5/20/26 4:40:25 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ROIV alert in real time by email
    S-8 1 dp242198_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on May 20, 2026

    Registration No. 333-______

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    FORM S-8
    REGISTRATION STATEMENT
    UNDER THE SECURITIES ACT OF 1933

     

    ROIVANT SCIENCES LTD.
    (Exact name of registrant as specified in its charter)

     

    Bermuda 98-1173944
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer
    Identification No.)

     

    7th Floor
    50 Broadway
    London SW1H 0DB
    United Kingdom

     

    1 Pennsylvania Plaza
    Floor 54
    New York, NY 10119
    United States1

     

    Viaduktstrasse 8
    4051 Basel
    Switzerland1

     

    Telephone: +44 207 400 3347
    (Addresses of Principal Executive Offices)

     

    ROIVANT SCIENCES LTD. 2021 EQUITY INCENTIVE PLAN
    (Full Title of the Plan)

     

    Corporation Service Company
    251 Little Falls Drive
    Wilmington, DE 19808
    Telephone: (800) 927-9801
    (Name and Address for Agent of Service)
    (Telephone number, Including Area Code, of Agent For Service)

     

     

     

    Copies of all correspondence to:
    Derek J. Dostal
    Stephen A. Byeff
    Davis Polk & Wardwell LLP
    450 Lexington Avenue
    New York, NY 10017
    (212) 450-4000

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer  ☑     Accelerated filer                   ☐
    Non-accelerated filer    ☐     Smaller reporting company  ☐
          Emerging growth company  ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

    1 Addresses of wholly-owned subsidiaries of the Registrant.

     

     

     

    EXPLANATORY NOTE
    REGISTRATION OF ADDITIONAL SHARES
    PURSUANT TO GENERAL INSTRUCTION E

     

    Pursuant to General Instruction E to Form S-8, the Registrant is filing this Registration Statement with the U.S. Securities and Exchange Commission (the “Commission”) to register additional shares of the Registrant’s Common Stock for issuance under the Roivant Sciences Ltd. 2021 Equity Incentive Plan (the “Plan”), pursuant to the provision of the Plan that provides for automatic annual increases in the number of shares reserved for issuance thereunder. This Registration Statement hereby incorporates by reference the contents of the Registrant’s registration statement on Form S-8 filed with the Commission on October 8, 2021 (File No. 333-260173), the registration statement on Form S-8 filed with the Commission on June 28, 2022 (File No. 333-265867), the registration statement on Form S-8 filed with the Commission on June 29, 2023 (File No. 333-273000), and the registration statement on Form S-8 filed with the Commission on July 26, 2024 (File No. 333-281061), in each case to the extent not superseded hereby.

     

    PART I

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    The documents containing the information specified in Item 1 and Item 2 of Part I of Form S-8 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”). In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.  Incorporation of Documents by Reference.

     

    The following documents are incorporated herein by reference:

     

    (a) the Registrant’s annual report on Form 10-K for the fiscal year ended March 31, 2026, filed with the Commission on May 20, 2025 (File No. 001-40782) (the “Annual Report”);

     

    (b) all other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (a) above; and

     

    (c) The description of the Registrant’s securities registered pursuant to Section 12 of the Exchange Act (filed as Exhibit 4.2 to the Registrant’s Annual Report).

     

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of this Registration Statement and prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, are incorporated by reference in this Registration Statement and are a part hereof from the date of filing of such documents; except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current Items 2.02 or 7.01 of Form 8-K that is not deemed filed under such provisions. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

    Item 8.  Exhibits.

     

    Exhibit
    Number 

     
    3.1

    Memorandum of Association of Roivant Sciences Ltd. (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Registration Statement on Form S-4/A (File No. 333-256165), as amended, filed with the Commission on May 14, 2021) 

    3.2

    Amended and Restated Bye-laws of Roivant Sciences Ltd. (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40782), filed with the Commission on October 1, 2021) 

    5.1*

    Opinion of Conyers Dill & Pearman Limited 

    23.1* Consent of Ernst & Young LLP
    23.2* Consent of Conyers Dill & Pearman Limited (included in Exhibit 5.1)
    24.1* Power of Attorney (included on the signature page hereto)
    99.1 Roivant Sciences Ltd. 2021 Equity Incentive Plan (incorporated herein by reference to Exhibit 99.1 to the Registrant’s Registration Statement on Form S-8 (File No. 333-260173), filed with the Commission on October 8, 2021)
    107.1* Filing Fee Table

     

    * Filed herewith

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in London, UK, on the 20th day of May 2026.

     

      ROIVANT SCIENCES LTD.
       
       
      By: /s/ Keyur Parekh
      Name: Keyur Parekh
      Title: Authorized Signatory

     

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below, constitutes and appoints Richard Pulik, Jo Chen and Keyur Parekh and each or any one of them, our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, to do any and all acts and things and execute, in the name of the undersigned, any and all instruments which said attorneys-in-fact and agents may deem necessary or advisable in order to enable Roivant Sciences Ltd. to comply with the Securities Act of 1933, as amended, and any requirements of the Securities and Exchange Commission in respect thereof, in connection with the filing with the Securities and Exchange Commission of one or more registration statements on Form S-8 under the Securities Act of 1933, as amended, including, specifically, but without limitation, power and authority to sign the name of the undersigned to any such registration statement, and any amendments to any such registration statement (including post-effective amendments), and to file the same with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, to sign any and all applications, registration statements, notices or other documents necessary or advisable to comply with applicable state securities laws, and to file the same, together with other documents in connection therewith with the appropriate state securities authorities, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and to perform each and every act and thing requisite or necessary to be done in and about the premises, as fully and to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them, or their substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.  

     

    Signature   Title   Date
             
             
    /s/ Matthew Gline   Chief Executive Officer & Director   May 20, 2026
    Matthew Gline   (principal executive officer)    
             
             
    /s/ Richard Pulik   Chief Financial Officer   May 20, 2026
    Richard Pulik   (principal financial officer)    
             
             
    /s/ Jenni Humes   Chief Accounting Officer   May 20, 2026
    Jenni Humes   (principal accounting officer)    
             
             
    /s/ Keith Manchester   Director   May 20, 2026
    Keith Manchester        
             
             
    /s/ Ilan Oren   Director   May 20, 2026
    Ilan Oren        
             
             
    /s/ Daniel Gold   Director   May 20, 2026
    Daniel Gold        
             
             
    /s/ Melissa Epperly   Director   May 20, 2026
    Melissa Epperly        
             
             
    /s/ Meghan FitzGerald   Director   May 20, 2026
    Meghan FitzGerald        
             
             
    /s/ James C. Momtazee   Director   May 20, 2026
    James C. Momtazee        
             
             
    /s/ Mayukh Sukhatme   Director   May 20, 2026
    Mayukh Sukhatme        

     

     

    Get the next $ROIV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ROIV

    DatePrice TargetRatingAnalyst
    3/20/2026$35.00Outperform
    Bernstein
    9/2/2025$16.00Buy
    Citigroup
    7/10/2025$19.00Buy
    Goldman
    2/15/2024$17.00Outperform
    Wolfe Research
    1/5/2024$20.00Overweight
    Piper Sandler
    12/12/2023$14.00Buy
    Deutsche Bank
    10/17/2023$17.00Buy
    Guggenheim
    6/8/2023$10.50Neutral
    BofA Securities
    More analyst ratings

    $ROIV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Gline Matthew bought $49,957 worth of shares (3,315 units at $15.07), increasing direct ownership by 0.02% to 17,287,081 units (SEC Form 4)

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    9/18/25 7:28:11 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ROIV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bernstein initiated coverage on Roivant Sciences with a new price target

    Bernstein initiated coverage of Roivant Sciences with a rating of Outperform and set a new price target of $35.00

    3/20/26 8:36:50 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Roivant Sciences with a new price target

    Citigroup initiated coverage of Roivant Sciences with a rating of Buy and set a new price target of $16.00

    9/2/25 8:40:38 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on Roivant Sciences with a new price target

    Goldman resumed coverage of Roivant Sciences with a rating of Buy and set a new price target of $19.00

    7/10/25 9:00:08 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ROIV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

    IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026 Brepocitinib granted Breakthrough Therapy Designation for the treatment of cutaneous sarcoidosis (CS) based on positive Phase 2 data; potentially registrational trial of brepocitinib in lichen planopilaris (LPP) enrolled its first subjects in March 2026 Commercial launch of brepocitinib in dermatomyositis (DM) is expected by the end of September 2026, and topline Phase 3 data for brepocitinib in no

    5/20/26 7:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

    BASEL, Switzerland and LONDON and NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 20, 2026, to report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the confere

    5/11/26 4:05:00 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

    DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update at 8:00 a.m. ET on Wednesday, May 20, 2026. To access the Roivant (NASDAQ:ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "News & Events" in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant's website after the conference call. About Immunovant  Immunova

    5/11/26 4:05:00 PM ET
    $IMVT
    $ROIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ROIV
    SEC Filings

    View All

    SEC Form S-8 filed by Roivant Sciences Ltd.

    S-8 - Roivant Sciences Ltd. (0001635088) (Filer)

    5/20/26 4:40:25 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Roivant Sciences Ltd.

    10-K - Roivant Sciences Ltd. (0001635088) (Filer)

    5/20/26 7:17:14 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roivant Sciences Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Roivant Sciences Ltd. (0001635088) (Filer)

    5/20/26 7:14:10 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ROIV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & Immunovant CEO Venker Eric exercised 200,000 shares at a strike of $3.85, sold $6,054,000 worth of shares (200,000 units at $30.27) and covered exercise/tax liability with 34,483 shares, decreasing direct ownership by 2% to 1,613,063 units (SEC Form 4) (withholding obligation)

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    5/22/26 6:25:47 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Pulik Richard covered exercise/tax liability with 18,962 shares, decreasing direct ownership by 6% to 278,549 units (SEC Form 4) to satisfy withholding tax

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    5/22/26 6:22:17 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Venker Eric

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    4/22/26 6:27:47 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ROIV
    Financials

    Live finance-specific insights

    View All

    Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

    IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026 Brepocitinib granted Breakthrough Therapy Designation for the treatment of cutaneous sarcoidosis (CS) based on positive Phase 2 data; potentially registrational trial of brepocitinib in lichen planopilaris (LPP) enrolled its first subjects in March 2026 Commercial launch of brepocitinib in dermatomyositis (DM) is expected by the end of September 2026, and topline Phase 3 data for brepocitinib in no

    5/20/26 7:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

    BASEL, Switzerland and LONDON and NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 20, 2026, to report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the confere

    5/11/26 4:05:00 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

    DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update at 8:00 a.m. ET on Wednesday, May 20, 2026. To access the Roivant (NASDAQ:ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "News & Events" in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant's website after the conference call. About Immunovant  Immunova

    5/11/26 4:05:00 PM ET
    $IMVT
    $ROIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ROIV
    Leadership Updates

    Live Leadership Updates

    View All

    Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600

    NEW YORK, March 26, 2024 /PRNewswire/ -- Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector April 1, 2024 S&P MidCap 400 Addition Roivant Sciences ROIV Health Care S&P MidCap 400 Deletion Sunrun RUN In

    3/26/24 6:22:00 PM ET
    $PGTI
    $ROIV
    $RUN
    Building Products
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

    BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately. Dr. Sukhatme will fill a newly created Class III seat on the Board of Directors, increasing the Board of Directors to eight members in total. "I'm thrilled to be adding Mayukh to our board. Mayukh has been with the company since almost the very beginning, and his contributions are too many to enumerate here. He has helped find and guide all of our key pipeline programs, and I am confident that his voice on our board will continue to further our important work for patients. It continue

    11/10/23 8:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer

      BOSTON, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company, is pleased to announce the appointment of Vincent Hennemand as Chief Executive Officer (CEO). Vincent Hennemand is a seasoned executive with a distinguished career in the pharmaceutical and biotechnology industry. With an exceptional track record of leadership, a passion for advancing healthcare, novel classes of therapeutics, and in-depth experience in immunology therapies, Vincent is poised to guide Covant Therapeutics into a new era of growth, innovation, and patient-centric excellence. Vincent joins Covant Therapeutics from his previous role as COO at Intergalactic T

    10/13/23 8:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ROIV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

    SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

    11/14/24 4:31:06 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

    SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

    11/12/24 4:58:58 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Roivant Sciences Ltd.

    SC 13G - Roivant Sciences Ltd. (0001635088) (Subject)

    11/12/24 10:34:18 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care